Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme. (8th March 2017)

• Record Type: Journal Article
• Authors: Hézode, Christophe; Lebray, Pascal; De Ledinghen, Victor; Zoulim, Fabien; Di Martino, Vincent; Boyer, Nathalie; Larrey, Dominique; Botta‐Fridlund, Danielle; Silvain, Christine; Fontaine, Hélène; D'Alteroche, Louis; Leroy, Vincent; Bourliere, Marc; Hubert‐Fouchard, Isabelle; Guyader, Dominique; Rosa, Isabelle; Nguyen‐Khac, Eric; Fedchuk, Larysa; Akremi, Raoudha; Bennai, Yacia; Filipovics, Anne; Zhao, Yue; Bronowicki, Jean‐Pierre
• Is Part Of: Liver international. Volume 37:Number 9(2017)
• Page Start: 1314
• Page End: 1324
• Publication Date: 2017-03-08
• Subjects: compassionate use -- daclatasvir -- genotype 3 -- hepatitis C -- real‐world data -- sofosbuvir; Liver -- Periodicals; Liver -- Diseases -- Periodicals; 616.362
• DOI: 10.1111/liv.13383
• Languages: English
• ISSNs: 1478-3223

Abstract

Abstract: Background & Aims: Optimally effective treatment for hepatitis C virus genotype 3 (GT3) is urgently needed, particularly in advanced liver disease. Daclatasvir plus sofosbuvir was efficacious in phase 3 studies. Real‐world data for daclatasvir+sofosbuvir in advanced GT3 infection are presented from the French Temporary Authorisation for Use programme, which allowed patients in need without other treatment options access to daclatasvir ahead of its market authorization. Methods: Patients with F3/F4 fibrosis and/or extrahepatic hepatitis C virus manifestations, post‐liver transplant hepatitis C virus recurrence and/or indication for liver/kidney transplant, were treated with daclatasvir+sofosbuvir (60+400 mg daily) for a recommended duration of 24 weeks. Addition of ribavirin and/or shorter treatment was at physician's discretion. The primary efficacy analysis was sustained virological response at post‐treatment week 12 (SVR12; modified intention‐to‐treat). Safety was assessed by spontaneous adverse event reporting. Results: The efficacy population comprised 333 patients, mostly cirrhotic (77%, of whom 18% were decompensated) and treatment experienced (72%). After 24 weeks of daclatasvir+sofosbuvir, SVR12 was 89% (174/196) overall (95% CI 83.6‐92.5%), 98% (43/44) without cirrhosis (95% CI 88.2‐99.6%) and 86% (129/150) with any degree of cirrhosis (95% CI 79.5‐90.7%), without SVR12 increase in those who received additional ribavirin for 24 weeks (SVR12 82% [50/61; 95% CI 70.5‐89.6%]). Among 516 GT3‐infected patients with safety data, 5 discontinued for adverse events and 11 died. Conclusions: Daclatasvir+sofosbuvir achieved high SVR12 rates and was well tolerated in this large real‐world cohort of GT3‐infected patients with advanced liver disease, without benefit of ribavirin in those treated 24 weeks.